Abstract
Primary Sjögren's syndrome (pSS) is an autoimmune disorder characterised by immune-driven damage to the exocrine glands, leading to diminished salivary and tear production. While the pathogenesis of pSS remains incompletely understood, its clinical presentations vary widely, and no specific treatments are currently available. Toll-like receptor 7 (TLR7) belongs to the Toll-like receptor family and is crucial for the innate immune response, notably in recognising pathogenic patterns. TLR7 is predominantly found in the endoplasmic reticulum (ER) and endosomes, where it identifies single-stranded RNA (ssRNA). Upon ligand binding, TLR7 activates the Myd88-dependent signalling cascade, eliciting an immune response.Dysregulation and variations in TLR7 expression are implicated in several autoimmune disorders. In genetically predisposed individuals, factors such as infections, endocrinological abnormality and metabolic abnormalities can cause TLR7 dysregulation, aggravating pSS symptoms and progression. While studies on TLR7 in pSS are limited, they offer insights into the disease's pathophysiological processes, vital for the treatment and prognosis. This article explores the mechanisms of TLR7 dysregulation, its involvement in pSS pathogenesis, and prospective therapeutic significance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.